Company Encyclopedia
View More
name
iShares Global Healthcare
IXJ.US
News
View More

10:30 ET Clinical Chemistry Analyzers Market worth $20.86 billion by 2030 | MarketsandMarkets™

The clinical chemistry analyzers market is projected to grow from $25.92 billion in 2025 to $20.86 billion by 2030, at a CAGR of 5.6%. Growth is driven by rising chronic diseases, an aging population, and point-of-care testing. North America leads the market, with hospitals & clinics as the largest end-user segment. Lipid profile tests are expected to grow fastest due to obesity-related health issues. Major companies include Abbott Laboratories, Roche, and Siemens Healthineers.

prnewswire·
US
ABT
+0.07%
DE
SIE
0.00%
prnewswire·
US
ABT
+0.07%
DE
SIE
0.00%

J&J directs a new campaign with Naomi Watts in the spotlight

Johnson & Johnson has launched a new campaign with actress Naomi Watts to promote vision health among women over 40. The initiative aims to integrate eye exams into self-care routines, highlighting the importance of eye health in overall well-being. J&J's vision portfolio includes treatments for age-related conditions, and the campaign seeks to encourage routine eye checks. A survey commissioned by J&J found that while many value clear vision, a significant number neglect regular eye exams. The campaign aligns with Watts' advocacy for health and wellness in aging.

Fiercepharma·
US
JNJ
-0.49%
Fiercepharma·
US
JNJ
-0.49%

Dividend Roundup: Microsoft, UnitedHealth Group, Analog Devices, Nucor, and more

Dividend Roundup: Microsoft, UnitedHealth Group, Analog Devices, Nucor, and more

businessinsider·
US
NU
-0.82%
US
NUE
-0.16%
US
UNH
-0.19%
businessinsider·
US
NU
-0.82%
US
NUE
-0.16%
US
UNH
-0.19%

Knuff & Co LLC Sells 3,559 Shares of Thermo Fisher Scientific Inc. $TMO

Knuff & Co LLC reduced its stake in Thermo Fisher Scientific Inc. by 34.8% in Q2, selling 3,559 shares. Thermo Fisher's stock opened at $580.61, with a market cap of $218.14 billion. The company reported Q3 earnings of $5.79 per share, surpassing estimates. A $5 billion share buyback plan was announced, indicating confidence in undervaluation. A quarterly dividend of $0.43 per share was also declared.

Market Beat·
US
TMO
-0.54%
Market Beat·
US
TMO
-0.54%

M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV

M Holdings Securities Inc. increased its holdings in AbbVie Inc. by 68.6% in Q2, owning 16,979 shares worth $3,121,000. Several other institutional investors also adjusted their positions in AbbVie. Analysts have upgraded AbbVie's stock ratings, with a current average rating of "Moderate Buy" and a target price of $241.85. AbbVie reported Q3 earnings of $1.86 EPS, beating estimates, and increased its quarterly dividend to $1.73 per share. The company has a market cap of $404.17 billion.

Market Beat·
US
ABBV
-1.35%
Market Beat·
US
ABBV
-1.35%
© 2025 Longbridge｜Disclaimer